nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Rhinorrhoea—Cisplatin—bone cancer	0.0162	0.0174	CcSEcCtD
Doxylamine—Loss of libido—Methotrexate—bone cancer	0.0156	0.0167	CcSEcCtD
Doxylamine—Body temperature decreased—Epirubicin—bone cancer	0.012	0.0129	CcSEcCtD
Doxylamine—Hypothermia—Epirubicin—bone cancer	0.012	0.0129	CcSEcCtD
Doxylamine—Lacrimation—Epirubicin—bone cancer	0.0114	0.0123	CcSEcCtD
Doxylamine—Hypothermia—Doxorubicin—bone cancer	0.0111	0.0119	CcSEcCtD
Doxylamine—Body temperature decreased—Doxorubicin—bone cancer	0.0111	0.0119	CcSEcCtD
Doxylamine—Polyuria—Cisplatin—bone cancer	0.0108	0.0116	CcSEcCtD
Doxylamine—Lacrimation—Doxorubicin—bone cancer	0.0106	0.0114	CcSEcCtD
Doxylamine—Liver disorder—Methotrexate—bone cancer	0.0105	0.0113	CcSEcCtD
Doxylamine—Haemolytic anaemia—Cisplatin—bone cancer	0.0105	0.0113	CcSEcCtD
Doxylamine—Redness—Epirubicin—bone cancer	0.00996	0.0107	CcSEcCtD
Doxylamine—Redness—Doxorubicin—bone cancer	0.00922	0.00991	CcSEcCtD
Doxylamine—Irritability—Cisplatin—bone cancer	0.00908	0.00976	CcSEcCtD
Doxylamine—Dehydration—Cisplatin—bone cancer	0.00884	0.00951	CcSEcCtD
Doxylamine—Orthostatic hypotension—Cisplatin—bone cancer	0.00868	0.00934	CcSEcCtD
Doxylamine—Breast disorder—Cisplatin—bone cancer	0.00859	0.00924	CcSEcCtD
Doxylamine—Cramp muscle—Cisplatin—bone cancer	0.00856	0.00921	CcSEcCtD
Doxylamine—Nasopharyngitis—Cisplatin—bone cancer	0.0085	0.00914	CcSEcCtD
Doxylamine—Clemastine—CYP3A4—bone cancer	0.00825	0.118	CrCbGaD
Doxylamine—Pancreatitis—Cisplatin—bone cancer	0.00806	0.00866	CcSEcCtD
Doxylamine—Sweating increased—Cisplatin—bone cancer	0.008	0.00861	CcSEcCtD
Doxylamine—Bone disorder—Methotrexate—bone cancer	0.00796	0.00856	CcSEcCtD
Doxylamine—Abdominal discomfort—Cisplatin—bone cancer	0.00788	0.00847	CcSEcCtD
Doxylamine—Pancytopenia—Cisplatin—bone cancer	0.0078	0.00839	CcSEcCtD
Doxylamine—Bone disorder—Epirubicin—bone cancer	0.00745	0.00801	CcSEcCtD
Doxylamine—Lacrimation increased—Epirubicin—bone cancer	0.0073	0.00785	CcSEcCtD
Doxylamine—Bone disorder—Doxorubicin—bone cancer	0.00689	0.00741	CcSEcCtD
Doxylamine—Lacrimation increased—Doxorubicin—bone cancer	0.00675	0.00726	CcSEcCtD
Doxylamine—Bradycardia—Cisplatin—bone cancer	0.0067	0.0072	CcSEcCtD
Doxylamine—Toremifene—CYP3A4—bone cancer	0.00654	0.0933	CrCbGaD
Doxylamine—Urinary tract disorder—Cisplatin—bone cancer	0.0065	0.00699	CcSEcCtD
Doxylamine—Urethral disorder—Cisplatin—bone cancer	0.00645	0.00693	CcSEcCtD
Doxylamine—Eye disorder—Cisplatin—bone cancer	0.00615	0.00661	CcSEcCtD
Doxylamine—Cardiac disorder—Cisplatin—bone cancer	0.0061	0.00656	CcSEcCtD
Doxylamine—Flushing—Cisplatin—bone cancer	0.0061	0.00656	CcSEcCtD
Doxylamine—Polyuria—Methotrexate—bone cancer	0.00594	0.00639	CcSEcCtD
Doxylamine—Immune system disorder—Cisplatin—bone cancer	0.00594	0.00639	CcSEcCtD
Doxylamine—Mediastinal disorder—Cisplatin—bone cancer	0.00593	0.00637	CcSEcCtD
Doxylamine—Erythema—Cisplatin—bone cancer	0.00573	0.00616	CcSEcCtD
Doxylamine—Cyclobenzaprine—CYP3A4—bone cancer	0.00565	0.0806	CrCbGaD
Doxylamine—Muscle spasms—Cisplatin—bone cancer	0.00551	0.00592	CcSEcCtD
Doxylamine—Disopyramide—CYP3A4—bone cancer	0.00542	0.0773	CrCbGaD
Doxylamine—Tremor—Cisplatin—bone cancer	0.00536	0.00577	CcSEcCtD
Doxylamine—Ill-defined disorder—Cisplatin—bone cancer	0.00531	0.00571	CcSEcCtD
Doxylamine—Malaise—Cisplatin—bone cancer	0.00516	0.00555	CcSEcCtD
Doxylamine—Leukopenia—Cisplatin—bone cancer	0.00513	0.00551	CcSEcCtD
Doxylamine—Irritability—Methotrexate—bone cancer	0.00498	0.00536	CcSEcCtD
Doxylamine—Convulsion—Cisplatin—bone cancer	0.00496	0.00534	CcSEcCtD
Doxylamine—Mood swings—Methotrexate—bone cancer	0.00494	0.00532	CcSEcCtD
Doxylamine—Diplopia—Epirubicin—bone cancer	0.00488	0.00525	CcSEcCtD
Doxylamine—Anxiety—Cisplatin—bone cancer	0.00486	0.00522	CcSEcCtD
Doxylamine—Discomfort—Cisplatin—bone cancer	0.00482	0.00518	CcSEcCtD
Doxylamine—Affect lability—Epirubicin—bone cancer	0.00481	0.00517	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—bone cancer	0.00471	0.00507	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.0047	0.00505	CcSEcCtD
Doxylamine—Anaphylactic shock—Cisplatin—bone cancer	0.00467	0.00503	CcSEcCtD
Doxylamine—Carbinoxamine—CYP3A4—bone cancer	0.00465	0.0663	CrCbGaD
Doxylamine—Mood swings—Epirubicin—bone cancer	0.00463	0.00497	CcSEcCtD
Doxylamine—Nervous system disorder—Cisplatin—bone cancer	0.00458	0.00493	CcSEcCtD
Doxylamine—Thrombocytopenia—Cisplatin—bone cancer	0.00458	0.00492	CcSEcCtD
Doxylamine—Tachycardia—Cisplatin—bone cancer	0.00456	0.0049	CcSEcCtD
Doxylamine—Dehydration—Epirubicin—bone cancer	0.00454	0.00488	CcSEcCtD
Doxylamine—Diplopia—Doxorubicin—bone cancer	0.00452	0.00486	CcSEcCtD
Doxylamine—Hyperhidrosis—Cisplatin—bone cancer	0.00452	0.00486	CcSEcCtD
Doxylamine—Orthostatic hypotension—Epirubicin—bone cancer	0.00446	0.0048	CcSEcCtD
Doxylamine—Anorexia—Cisplatin—bone cancer	0.00445	0.00479	CcSEcCtD
Doxylamine—Affect lability—Doxorubicin—bone cancer	0.00445	0.00478	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—bone cancer	0.00442	0.00475	CcSEcCtD
Doxylamine—Levomethadyl Acetate—CYP3A4—bone cancer	0.00442	0.063	CrCbGaD
Doxylamine—Breast disorder—Epirubicin—bone cancer	0.00441	0.00474	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.0044	0.00473	CcSEcCtD
Doxylamine—Hypotension—Cisplatin—bone cancer	0.00437	0.0047	CcSEcCtD
Doxylamine—Nasopharyngitis—Epirubicin—bone cancer	0.00437	0.0047	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—bone cancer	0.00432	0.00465	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—bone cancer	0.00428	0.00461	CcSEcCtD
Doxylamine—Mood swings—Doxorubicin—bone cancer	0.00428	0.0046	CcSEcCtD
Doxylamine—Dehydration—Doxorubicin—bone cancer	0.0042	0.00452	CcSEcCtD
Doxylamine—Dyspnoea—Cisplatin—bone cancer	0.00417	0.00448	CcSEcCtD
Doxylamine—Pancreatitis—Epirubicin—bone cancer	0.00414	0.00445	CcSEcCtD
Doxylamine—Orthostatic hypotension—Doxorubicin—bone cancer	0.00413	0.00444	CcSEcCtD
Doxylamine—Breast disorder—Doxorubicin—bone cancer	0.00408	0.00439	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00407	0.00437	CcSEcCtD
Doxylamine—Decreased appetite—Cisplatin—bone cancer	0.00406	0.00437	CcSEcCtD
Doxylamine—Nasopharyngitis—Doxorubicin—bone cancer	0.00404	0.00434	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00403	0.00434	CcSEcCtD
Doxylamine—Brompheniramine—CYP3A4—bone cancer	0.00403	0.0575	CrCbGaD
Doxylamine—Drowsiness—Methotrexate—bone cancer	0.00402	0.00432	CcSEcCtD
Doxylamine—Depression—Methotrexate—bone cancer	0.00401	0.00431	CcSEcCtD
Doxylamine—Pancytopenia—Epirubicin—bone cancer	0.00401	0.00431	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00399	0.00429	CcSEcCtD
Doxylamine—Chlorphenamine—CYP3A4—bone cancer	0.00395	0.0564	CrCbGaD
Doxylamine—Sweating—Methotrexate—bone cancer	0.00385	0.00415	CcSEcCtD
Doxylamine—Feeling abnormal—Cisplatin—bone cancer	0.00385	0.00414	CcSEcCtD
Doxylamine—Pancreatitis—Doxorubicin—bone cancer	0.00383	0.00412	CcSEcCtD
Doxylamine—Dextropropoxyphene—CYP3A4—bone cancer	0.00382	0.0545	CrCbGaD
Doxylamine—Drowsiness—Epirubicin—bone cancer	0.00376	0.00405	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—bone cancer	0.00375	0.00404	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00373	0.00401	CcSEcCtD
Doxylamine—Pancytopenia—Doxorubicin—bone cancer	0.00371	0.00399	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—bone cancer	0.00361	0.00388	CcSEcCtD
Doxylamine—Sweating—Epirubicin—bone cancer	0.00361	0.00388	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—bone cancer	0.00356	0.00383	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—bone cancer	0.00354	0.0038	CcSEcCtD
Doxylamine—Agranulocytosis—Epirubicin—bone cancer	0.00351	0.00378	CcSEcCtD
Doxylamine—Drowsiness—Doxorubicin—bone cancer	0.00348	0.00374	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00345	0.00371	CcSEcCtD
Doxylamine—Hypersensitivity—Cisplatin—bone cancer	0.00344	0.0037	CcSEcCtD
Doxylamine—Bradycardia—Epirubicin—bone cancer	0.00344	0.0037	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—bone cancer	0.00341	0.00367	CcSEcCtD
Doxylamine—Hepatitis—Epirubicin—bone cancer	0.00338	0.00363	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—bone cancer	0.00337	0.00363	CcSEcCtD
Doxylamine—Asthenia—Cisplatin—bone cancer	0.00335	0.00361	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—bone cancer	0.00335	0.0036	CcSEcCtD
Doxylamine—Benzphetamine—CYP3A4—bone cancer	0.00335	0.0478	CrCbGaD
Doxylamine—Sweating—Doxorubicin—bone cancer	0.00334	0.00359	CcSEcCtD
Doxylamine—Urinary tract disorder—Epirubicin—bone cancer	0.00334	0.00359	CcSEcCtD
Doxylamine—Atomoxetine—CYP3A4—bone cancer	0.00332	0.0474	CrCbGaD
Doxylamine—Urethral disorder—Epirubicin—bone cancer	0.00331	0.00356	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—bone cancer	0.00326	0.00351	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—bone cancer	0.00325	0.0035	CcSEcCtD
Doxylamine—Agranulocytosis—Doxorubicin—bone cancer	0.00325	0.00349	CcSEcCtD
Doxylamine—Diarrhoea—Cisplatin—bone cancer	0.0032	0.00344	CcSEcCtD
Doxylamine—Erythema multiforme—Epirubicin—bone cancer	0.00319	0.00343	CcSEcCtD
Doxylamine—Bradycardia—Doxorubicin—bone cancer	0.00318	0.00342	CcSEcCtD
Doxylamine—Eye disorder—Epirubicin—bone cancer	0.00316	0.00339	CcSEcCtD
Doxylamine—Erythema—Methotrexate—bone cancer	0.00314	0.00338	CcSEcCtD
Doxylamine—Flushing—Epirubicin—bone cancer	0.00313	0.00337	CcSEcCtD
Doxylamine—Cardiac disorder—Epirubicin—bone cancer	0.00313	0.00337	CcSEcCtD
Doxylamine—Hepatitis—Doxorubicin—bone cancer	0.00313	0.00336	CcSEcCtD
Doxylamine—Urinary tract disorder—Doxorubicin—bone cancer	0.00309	0.00332	CcSEcCtD
Doxylamine—Urethral disorder—Doxorubicin—bone cancer	0.00306	0.00329	CcSEcCtD
Doxylamine—Immune system disorder—Epirubicin—bone cancer	0.00305	0.00328	CcSEcCtD
Doxylamine—Mediastinal disorder—Epirubicin—bone cancer	0.00304	0.00327	CcSEcCtD
Doxylamine—Vomiting—Cisplatin—bone cancer	0.00297	0.0032	CcSEcCtD
Doxylamine—Erythema multiforme—Doxorubicin—bone cancer	0.00296	0.00318	CcSEcCtD
Doxylamine—Rash—Cisplatin—bone cancer	0.00295	0.00317	CcSEcCtD
Doxylamine—Dermatitis—Cisplatin—bone cancer	0.00294	0.00317	CcSEcCtD
Doxylamine—Erythema—Epirubicin—bone cancer	0.00294	0.00316	CcSEcCtD
Doxylamine—Eye disorder—Doxorubicin—bone cancer	0.00292	0.00314	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—bone cancer	0.00292	0.00314	CcSEcCtD
Doxylamine—Flushing—Doxorubicin—bone cancer	0.0029	0.00312	CcSEcCtD
Doxylamine—Cardiac disorder—Doxorubicin—bone cancer	0.0029	0.00312	CcSEcCtD
Doxylamine—Malaise—Methotrexate—bone cancer	0.00283	0.00305	CcSEcCtD
Doxylamine—Muscle spasms—Epirubicin—bone cancer	0.00283	0.00304	CcSEcCtD
Doxylamine—Immune system disorder—Doxorubicin—bone cancer	0.00282	0.00304	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—bone cancer	0.00282	0.00304	CcSEcCtD
Doxylamine—Mediastinal disorder—Doxorubicin—bone cancer	0.00282	0.00303	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—bone cancer	0.00281	0.00302	CcSEcCtD
Doxylamine—Nausea—Cisplatin—bone cancer	0.00278	0.00299	CcSEcCtD
Doxylamine—Ill-defined disorder—Epirubicin—bone cancer	0.00273	0.00293	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—bone cancer	0.00272	0.00293	CcSEcCtD
Doxylamine—Erythema—Doxorubicin—bone cancer	0.00272	0.00293	CcSEcCtD
Doxylamine—Agitation—Epirubicin—bone cancer	0.0027	0.00291	CcSEcCtD
Doxylamine—Malaise—Epirubicin—bone cancer	0.00265	0.00285	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—bone cancer	0.00264	0.00284	CcSEcCtD
Doxylamine—Vertigo—Epirubicin—bone cancer	0.00264	0.00284	CcSEcCtD
Doxylamine—Leukopenia—Epirubicin—bone cancer	0.00263	0.00283	CcSEcCtD
Doxylamine—Muscle spasms—Doxorubicin—bone cancer	0.00262	0.00281	CcSEcCtD
Doxylamine—Tamoxifen—CYP3A4—bone cancer	0.00261	0.0373	CrCbGaD
Doxylamine—Doxepin—CYP3A4—bone cancer	0.0026	0.0371	CrCbGaD
Doxylamine—Palpitations—Epirubicin—bone cancer	0.0026	0.00279	CcSEcCtD
Doxylamine—Methadone—CYP3A4—bone cancer	0.00259	0.0369	CrCbGaD
Doxylamine—Confusional state—Methotrexate—bone cancer	0.00259	0.00278	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—bone cancer	0.00256	0.00276	CcSEcCtD
Doxylamine—Convulsion—Epirubicin—bone cancer	0.00255	0.00274	CcSEcCtD
Doxylamine—Orphenadrine—CYP3A4—bone cancer	0.00254	0.0362	CrCbGaD
Doxylamine—Ill-defined disorder—Doxorubicin—bone cancer	0.00252	0.00271	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—bone cancer	0.00251	0.0027	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—bone cancer	0.00251	0.0027	CcSEcCtD
Doxylamine—Agitation—Doxorubicin—bone cancer	0.0025	0.00269	CcSEcCtD
Doxylamine—Anxiety—Epirubicin—bone cancer	0.00249	0.00268	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—bone cancer	0.00248	0.00267	CcSEcCtD
Doxylamine—Discomfort—Epirubicin—bone cancer	0.00247	0.00266	CcSEcCtD
Doxylamine—Malaise—Doxorubicin—bone cancer	0.00245	0.00264	CcSEcCtD
Doxylamine—Dry mouth—Epirubicin—bone cancer	0.00245	0.00263	CcSEcCtD
Doxylamine—Vertigo—Doxorubicin—bone cancer	0.00244	0.00263	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—bone cancer	0.00244	0.00263	CcSEcCtD
Doxylamine—Leukopenia—Doxorubicin—bone cancer	0.00244	0.00262	CcSEcCtD
Doxylamine—Confusional state—Epirubicin—bone cancer	0.00242	0.0026	CcSEcCtD
Doxylamine—Palpitations—Doxorubicin—bone cancer	0.0024	0.00259	CcSEcCtD
Doxylamine—Anaphylactic shock—Epirubicin—bone cancer	0.0024	0.00258	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—bone cancer	0.0024	0.00258	CcSEcCtD
Doxylamine—Convulsion—Doxorubicin—bone cancer	0.00236	0.00254	CcSEcCtD
Doxylamine—Nervous system disorder—Epirubicin—bone cancer	0.00235	0.00253	CcSEcCtD
Doxylamine—Thrombocytopenia—Epirubicin—bone cancer	0.00235	0.00253	CcSEcCtD
Doxylamine—Tachycardia—Epirubicin—bone cancer	0.00234	0.00252	CcSEcCtD
Doxylamine—Hyperhidrosis—Epirubicin—bone cancer	0.00232	0.00249	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—bone cancer	0.00232	0.00249	CcSEcCtD
Doxylamine—Promazine—CYP3A4—bone cancer	0.00231	0.033	CrCbGaD
Doxylamine—Anxiety—Doxorubicin—bone cancer	0.00231	0.00248	CcSEcCtD
Doxylamine—Discomfort—Doxorubicin—bone cancer	0.00229	0.00246	CcSEcCtD
Doxylamine—Anorexia—Epirubicin—bone cancer	0.00229	0.00246	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—bone cancer	0.00229	0.00246	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—bone cancer	0.00228	0.00245	CcSEcCtD
Doxylamine—Dry mouth—Doxorubicin—bone cancer	0.00227	0.00244	CcSEcCtD
Doxylamine—Hypotension—Epirubicin—bone cancer	0.00224	0.00241	CcSEcCtD
Doxylamine—Confusional state—Doxorubicin—bone cancer	0.00224	0.00241	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—bone cancer	0.00223	0.0024	CcSEcCtD
Doxylamine—Anaphylactic shock—Doxorubicin—bone cancer	0.00222	0.00239	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00221	0.00238	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—bone cancer	0.00221	0.00238	CcSEcCtD
Doxylamine—Nervous system disorder—Doxorubicin—bone cancer	0.00218	0.00234	CcSEcCtD
Doxylamine—Thrombocytopenia—Doxorubicin—bone cancer	0.00217	0.00234	CcSEcCtD
Doxylamine—Insomnia—Epirubicin—bone cancer	0.00217	0.00233	CcSEcCtD
Doxylamine—Tachycardia—Doxorubicin—bone cancer	0.00217	0.00233	CcSEcCtD
Doxylamine—Hyperhidrosis—Doxorubicin—bone cancer	0.00215	0.00231	CcSEcCtD
Doxylamine—Dyspnoea—Epirubicin—bone cancer	0.00214	0.0023	CcSEcCtD
Doxylamine—Somnolence—Epirubicin—bone cancer	0.00213	0.00229	CcSEcCtD
Doxylamine—Anorexia—Doxorubicin—bone cancer	0.00212	0.00228	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—bone cancer	0.00211	0.00227	CcSEcCtD
Doxylamine—Decreased appetite—Epirubicin—bone cancer	0.00209	0.00224	CcSEcCtD
Doxylamine—Hypotension—Doxorubicin—bone cancer	0.00207	0.00223	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00207	0.00223	CcSEcCtD
Doxylamine—Fatigue—Epirubicin—bone cancer	0.00207	0.00222	CcSEcCtD
Doxylamine—Constipation—Epirubicin—bone cancer	0.00205	0.00221	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—bone cancer	0.00204	0.00219	CcSEcCtD
Doxylamine—Imipramine—CYP3A4—bone cancer	0.00203	0.0289	CrCbGaD
Doxylamine—Amitriptyline—CYP3A4—bone cancer	0.00201	0.0287	CrCbGaD
Doxylamine—Insomnia—Doxorubicin—bone cancer	0.00201	0.00216	CcSEcCtD
Doxylamine—Dyspnoea—Doxorubicin—bone cancer	0.00198	0.00213	CcSEcCtD
Doxylamine—Feeling abnormal—Epirubicin—bone cancer	0.00198	0.00213	CcSEcCtD
Doxylamine—Somnolence—Doxorubicin—bone cancer	0.00197	0.00212	CcSEcCtD
Doxylamine—Decreased appetite—Doxorubicin—bone cancer	0.00193	0.00208	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00192	0.00206	CcSEcCtD
Doxylamine—Fatigue—Doxorubicin—bone cancer	0.00191	0.00206	CcSEcCtD
Doxylamine—Urticaria—Epirubicin—bone cancer	0.00191	0.00205	CcSEcCtD
Doxylamine—Constipation—Doxorubicin—bone cancer	0.0019	0.00204	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—bone cancer	0.00189	0.00203	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—bone cancer	0.00184	0.00198	CcSEcCtD
Doxylamine—Feeling abnormal—Doxorubicin—bone cancer	0.00183	0.00197	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—bone cancer	0.00181	0.00195	CcSEcCtD
Doxylamine—Hypersensitivity—Epirubicin—bone cancer	0.00177	0.0019	CcSEcCtD
Doxylamine—Urticaria—Doxorubicin—bone cancer	0.00176	0.0019	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—bone cancer	0.00175	0.00189	CcSEcCtD
Doxylamine—Asthenia—Epirubicin—bone cancer	0.00172	0.00185	CcSEcCtD
Doxylamine—Pruritus—Epirubicin—bone cancer	0.0017	0.00183	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—bone cancer	0.0017	0.00182	CcSEcCtD
Doxylamine—Diarrhoea—Epirubicin—bone cancer	0.00164	0.00177	CcSEcCtD
Doxylamine—Hypersensitivity—Doxorubicin—bone cancer	0.00164	0.00176	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—bone cancer	0.00163	0.00175	CcSEcCtD
Doxylamine—Rash—Methotrexate—bone cancer	0.00162	0.00174	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—bone cancer	0.00162	0.00174	CcSEcCtD
Doxylamine—Asthenia—Doxorubicin—bone cancer	0.00159	0.00171	CcSEcCtD
Doxylamine—Dizziness—Epirubicin—bone cancer	0.00159	0.00171	CcSEcCtD
Doxylamine—Pruritus—Doxorubicin—bone cancer	0.00157	0.00169	CcSEcCtD
Doxylamine—Vomiting—Epirubicin—bone cancer	0.00153	0.00164	CcSEcCtD
Doxylamine—Nausea—Methotrexate—bone cancer	0.00152	0.00164	CcSEcCtD
Doxylamine—Diarrhoea—Doxorubicin—bone cancer	0.00152	0.00163	CcSEcCtD
Doxylamine—Rash—Epirubicin—bone cancer	0.00151	0.00163	CcSEcCtD
Doxylamine—Dermatitis—Epirubicin—bone cancer	0.00151	0.00163	CcSEcCtD
Doxylamine—Dizziness—Doxorubicin—bone cancer	0.00147	0.00158	CcSEcCtD
Doxylamine—Nausea—Epirubicin—bone cancer	0.00143	0.00153	CcSEcCtD
Doxylamine—Vomiting—Doxorubicin—bone cancer	0.00141	0.00152	CcSEcCtD
Doxylamine—Rash—Doxorubicin—bone cancer	0.0014	0.00151	CcSEcCtD
Doxylamine—Dermatitis—Doxorubicin—bone cancer	0.0014	0.0015	CcSEcCtD
Doxylamine—Nausea—Doxorubicin—bone cancer	0.00132	0.00142	CcSEcCtD
